Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 3Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 29Head & Neck 12Gastrointestinal 9CNS 5Breast 4Other solid neoplasm 3Sarcoma 2Gynecologic 2Tumor-Agnostic 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 4

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Endostatins × Breast × Clear all
NCT03907098 2019-04-08

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Unknown
50 enrolled
Breast

Breast Neoplasms

NCT02489409 2017-07-17

Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

Xinjiang Medical University

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT01479036 2011-11-24

CBCRT01

Xijing Hospital

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms

NCT00604435 2010-01-20

Neoadjuvant Endostatin and Chemotherapy for Breast Cancer

Xijing Hospital

Phase 2 Completed
69 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡